Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis

Published:2024-06-19 Issue:7 Volume:14 Page:1849-1861
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Armstrong April W.,Alexis Andrew F.,Blauvelt Andrew,Silverberg Jonathan I.,Feeney Claire,Levenberg Mark,Chan Gary,Zhang Fan,Fostvedt Luke

Funder

Pfizer

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13555-024-01183-3.pdf

Reference23 articles.

1. Pfizer Limited. Cibinqo 100 mg film-coated tablets. Summary of product characteristics. Tadworth: Pfizer Limited; 2021.

2. Pfizer Japan Inc. Cibinqo™ (abrocitinib) tablets for oral use (50 mg, 100 mg, 200 mg). Tokyo: Pfizer Japan Inc.; 2021.

3. Pfizer Canada ULC. Cibinqo (abrocitinib). Product monograph. Kirkland: Pfizer Canada ULC; 2022.

4. European Medicines Agency. Cibinqo® (abrocitinib). Summary of product characteristics (SmPC). Pfizer Europe MA EEIG. Belgium: European Medicines Agency; 2024.

5. Pfizer Inc. Cibinqo (abrocitinib) tablets, for oral use. Prescribing information. New York: Pfizer Inc.; 2023.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP